TOKYO/NEW YORK -- An advisory panel under the U.S. Food and Drug Administration on Friday paved the way for the full approval of lecanemab, an Alzheimer's disease treatment developed by Japanese drugmaker Eisai and American partner Biogen.
The FDA had already given the drug a provisional green light in January under its Accelerated Approval pathway.
